Halo™ – Hybrid Fractional Laser

Patients treated with HALO experience great improvement to the appearance of skin. They can expect remarkable results in 1-2 treatments while older, non-hybrid technology often requires 5-6 treatments to demonstrate similar texture changes delivered from HALO in terms of pigment correction. The HALO patient experience is second-to-none: the treatment is extremely comfortable, only a topical anesthetic is recommended (no nerve blocks), and patients can apply makeup within 24 hours of the procedure.

HALO Indications

• Wrinkles and fine lines
• Sun damage/dyschromia
• Skin resurfacing
• Scar revision (including acne scars)
• Signs of aging
• Pigmented lesions
• Improves appearance of enlarged pores
• Medical dermatology/Actinic Keratoses

HALO can treat all skin types, on face and body. Popular off-face treatments include: neck, chest, arms, hands, and legs.

HALO by Sciton sets the standard for the future of laser resurfacing by providing a safe, tunable, and effective long-term hybrid option for resurfacing treatments.

Adding tunable ablation to a non-ablative treatment creates varying effects when different levels are used. Low levels of ablation (up to 20 microns) cause faster clearance of microscopic epidermal necrotic debris (MENDs). Heavier levels of ablation (up to 100 microns) seem to create a synergistic wound healing response. The clinical effect is ablative-like results with nearly non-ablative-like healing.

HALO Before and After 1 Treatment 1470 nm 400 µm coagulation, 20% density, 2940 nm 30 µm ablation, 19% density

• The 2940 nm wavelength targets the epidermis or top layer of the skin and is tunable between (20-100um) to precisely vaporize tissue in a controlled manner to address textural issues and pore size.
• The 1470 nm wavelength targets the dermis is tunable to (250-700um) to address deeper sun damage, stimulates collagenesis, and other dermal pigmentary issues.
• Each wavelength can be tuned independently for precise coverage and depth.

HALO Technology

Beyond the hybrid technology that makes HALO so unique are many features that help improve usability and safety.

Features include:

1. Integrated Cooling and Smoke Evacuation
2. Independently tunable 1470 nm and 2940 wavelengths
3. Dynamic Thermal Optimization DTO technology
4. Optical Navigation
5. Adjustable Beam Placement (ABP)
6. Available on the expandable JOULE platform

HALO offers the flexibility of completely turning off ablation for users that are not qualified to use an ablative laser (state by state regulation) or for those looking for the simplest laser treatments. Both the ablative and non-ablative laser wavelengths can be delivered in the same pass, and many permutations of depths and density coverage are possible.

INTEGRATED COOLING

The HALO hand piece includes integrated air cooling and smoke evacuation. The integrated cooling provides cold air across the treatment zone which provides patient comfort while smoke evacuation provides safety for the patient and operator. The integrated design makes it easy for treatments to be performed by one person.

DTO TECHNOLOGY

Dynamic Thermal Optimization (DTO) is built into HALO to automatically adjust the power of each individual 1470 nm pulse based on the temperature of the patient’s skin. This feature makes HALO the most precise, safe, comfortable, and consistent non-ablative technology on the market.

OPTICAL NAVIGATION

The high-speed optical navigation system on the HALO hand piece captures the motion of the hand piece hundreds of times every second to track the speed with extreme precision. Combining the optical navigation with sophisticated software to map the patient’s skin, the safety of the treatment increases and creates a consistent
treatment from beginning to end.

ABP (ADJUSTABLE BEAM PLACEMENT)

• Change both the size and position of the delivery beam
• Three beam sizes: 15 mm, 7 mm, or 4 mm
• Two beam placements: left or right
• Treat areas with distinct edges and linear scars

HALO’s Physician Interface

Adding tunable ablation to a non-ablative treatment creates varying effects when different levels of depth and densities are used. Using low levels of ablation (up to 20 microns) causes faster clearance of microscopic epidermal necrotic debris (MENDs). Heavier levels of ablation (up to 100 microns) create a synergistic wound healing response. The clinical effect is ablative-like results with nearly non-ablative-like healing.

During a non-ablative treatment, a column of the skin called the Micro Thermal Treatment Zone (MTZ) is heated to a temperature that necroses the epidermis and denatures dermal collagen. In the first 24 hours, the basal cell layer regenerates across the MTZs, under the necrosed epidermis, and then proliferates upwards, expelling the necrosed tissue. This necrosed tissue becomes small packets of debris called Microscopic Epidermal Necrotic Debris (MENDs) that are trapped under the stratum corneum, taking between 2 to 7 to days to clear. Performing a 20-micron ablation followed by coagulation allows faster removal of MENDs. By removing the stratum corneum, the MENDs are free to exit the skin within a day of forming. This results in 1 – 2 days faster healing time as compared to non-ablative treatments.

Ablating tissue creates a stronger wound healing response than just coagulating the tissue . This wound healing response can be optimized by adding more ablation during a HALO treatment. Adding up to 100 microns of ablation removes some of the tissue that would otherwise be necrosed near the surface, eliminating any MEND formation and limiting adverse events near the surface. In addition, the increased wound healing response in ablated tissue has a synergistic effect when combined with coagulated tissue though activation of Activator Protein 1 (AP-1) transcription factor leading to upregulation of Matrix Metalloproteinase (MMPs) which drive dermal remodeling . The combination of the ablated epidermis’ inflammatory response with the denaturing of the dermis’ collagen accounting for the greater, ablative-like results that are seen with a hybrid fractional treatment.